Explore the categories so you can find more about your search.

Categorie > Crohn's

Can-Fite: CF101 May Be Effective For The Treatment Of Crohn's Disease

Categorie : Crohn's
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, reports today that its CF101 drug may also be used to treat Crohn's disease, a serious gastrointestinal disorder. Can-Fite will present these findings at the annual meeting of the American College of Rheum ...

read more Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, reports today that its CF101 drug may also be used to treat Crohn's disease, a serious gastrointestinal disorder. Can-Fite will present these findings at the annual meeting of the American College of Rheum read more Wed Dec 2007 Wed Dec 2007

Bowel Surgery Should Not Be Last Resort, UK Study

Categorie : Crohn's
The threshold for deciding elective surgery for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease is too high says a new UK report. The result is that surgery is treated as a last resort resulting in too many emergency operations with poorer survival rates than if earlier e ...

read more The threshold for deciding elective surgery for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease is too high says a new UK report. The result is that surgery is treated as a last resort resulting in too many emergency operations with poorer survival rates than if earlier e read more Wed Dec 2007 Wed Dec 2007

New CIMZIA(R) Data Demonstrates Efficacy For Up To 18 Months In Patients With Crohn's Disease, With No Dose Escalation

Categorie : Crohn's
CIMZIA(R) (certolizumab pegol), the first and only PEGylated anti-TNF therapy, has been shown to maintain remission for up to 18 months in patients with Crohn's disease, according to new data presented at the 15th United European Gastroenterology Week (UEGW). The data also showed that some patients ...

read more CIMZIA(R) (certolizumab pegol), the first and only PEGylated anti-TNF therapy, has been shown to maintain remission for up to 18 months in patients with Crohn's disease, according to new data presented at the 15th United European Gastroenterology Week (UEGW). The data also showed that some patients read more Wed Dec 2007 Wed Dec 2007

Cytokine Announces Oral Efficacy Of Anti Cytokine Semapimod

Categorie : Crohn's
Cytokine PharmaSciences, Inc. (CPSI) announced development of an orally active form of semapimod, its synthetic anti cytokine compound. Semapimod is a potential treatment for inflammatory and autoimmune diseases including rheumatoid arthritis, Crohn's and psoriasis. The compound has previously been ...

read more Cytokine PharmaSciences, Inc. (CPSI) announced development of an orally active form of semapimod, its synthetic anti cytokine compound. Semapimod is a potential treatment for inflammatory and autoimmune diseases including rheumatoid arthritis, Crohn's and psoriasis. The compound has previously been read more Wed Dec 2007 Wed Dec 2007

Elan And Biogen Idec Announce That Fda Will Extend Regulatory Review Period For TysabriŽ For Crohn's Disease

Categorie : Crohn's
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) informed the companies that the Agency will extend its regulatory review of TYSABRIŽ (natalizumab) as a treatment for Crohn's disease by up to 3 months.The companies have been ...

read more Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) informed the companies that the Agency will extend its regulatory review of TYSABRIŽ (natalizumab) as a treatment for Crohn's disease by up to 3 months.The companies have been read more Wed Dec 2007 Wed Dec 2007

CHMP Adopts Negative Opinion On Appeal On European Application For Natalizumab For The Treatment Of Crohn's Disease

Categorie : Crohn's
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment fo ...

read more Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment fo read more Wed Dec 2007 Wed Dec 2007

Abbott Launches Humira (Adalimumab) For Crohn's Disease

Categorie : Crohn's
Abbott launches HUMIRA® (adalimumab) as a treatment for severe, active Crohn's disease. Adalimumab is the first fully-human tumour necrosis factor antagonist (anti-TNF) to receive a licence for Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract that impairs th ...

read more Abbott launches HUMIRA® (adalimumab) as a treatment for severe, active Crohn's disease. Adalimumab is the first fully-human tumour necrosis factor antagonist (anti-TNF) to receive a licence for Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract that impairs th read more Sun Oct 2007 Sun Oct 2007

Remicade® Receives EU Approval As First And Only Biologic Treatment For Paediatric Crohn's Disease

Categorie : Crohn's
The European Commission (EC) has approved a new indication for Remicade® (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and pr ...

read more The European Commission (EC) has approved a new indication for Remicade® (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and pr read more Sun Oct 2007 Sun Oct 2007

Protein C Signaling Impacts Inflammatory Bowel Disease

Categorie : Crohn's
Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, involves both immune and nonimmune cells. Previous studies have established that the vasculature of the gut mucosa is an important nonimmune component of intestinal inflammation and that the protein C (PC) signaling p ...

read more Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, involves both immune and nonimmune cells. Previous studies have established that the vasculature of the gut mucosa is an important nonimmune component of intestinal inflammation and that the protein C (PC) signaling p read more Sun Oct 2007 Sun Oct 2007

First-Step Test For Patients With Crohn's Disease Should Be PET/CT

Categorie : Crohn's
The molecular imaging power of PET/CT is invaluable in noninvasively monitoring Crohn's disease - a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people, according to a study released by Belgian scientists at the 54th Annual Meeting of SNM, the world's larg ...

read more The molecular imaging power of PET/CT is invaluable in noninvasively monitoring Crohn's disease - a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people, according to a study released by Belgian scientists at the 54th Annual Meeting of SNM, the world's larg read more Sun Oct 2007 Sun Oct 2007

Abbott's HUMIRA® (Adalimumab) Approved In The European Union For The Treatment Of Crohn's Disease

Categorie : Crohn's
Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA® (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and co ...

read more Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA® (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and co read more Sun Oct 2007 Sun Oct 2007

Elan And Biogen Idec Preparing To Appeal Ruling On European Application For Natalizumab For The Treatment Of Crohn's Disease

Categorie : Crohn's
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that they have been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the marketing application for the use of natalizumab ...

read more Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that they have been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the marketing application for the use of natalizumab read more Sun Oct 2007 Sun Oct 2007

Certolizumab Pego Found To Be Effective New Therapy For Patients With Crohn's Disease

Categorie : Crohn's
Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies. These findings were published in today's issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cau ...

read more Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies. These findings were published in today's issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cau read more Sun Oct 2007 Sun Oct 2007

Pivotal CIMZIA™ Data In Crohn's Disease Published In New England Journal Of Medicine

Categorie : Crohn's
Two pivotal Phase III clinical trials demonstrating the safety and sustained efficacy of CIMZIA™ (certolizumab pegol) in moderate-to-severe Crohn's disease (CD) were published in two articles in the July 19 issue of the New England Journal of Medicine (NEJM). [click link for full arti ...

read more Two pivotal Phase III clinical trials demonstrating the safety and sustained efficacy of CIMZIA™ (certolizumab pegol) in moderate-to-severe Crohn's disease (CD) were published in two articles in the July 19 issue of the New England Journal of Medicine (NEJM). [click link for full arti read more Sun Oct 2007 Sun Oct 2007

Gene Identified For Crohn's Disease In Children

Categorie : Crohn's
Pediatrics researchers have identified a gene variant that raises a child's risk of Crohn's disease, a chronic and painful condition attributed to inflammation of the gastrointestinal tract. The research reinforces previous results by German researchers, who found the same gene variant associated w ...

read more Pediatrics researchers have identified a gene variant that raises a child's risk of Crohn's disease, a chronic and painful condition attributed to inflammation of the gastrointestinal tract. The research reinforces previous results by German researchers, who found the same gene variant associated w read more Sun Oct 2007 Sun Oct 2007

First-time Link Between Food Intolerance And Illness

Categorie : Crohn's
Researchers from University College London have found compelling evidence for the first time to link food intolerances and serious illness.A six-month programme has shown potential links with foodstuffs and Crohn's Disease, and ulcerative colitis.The discovery could prompt an entire rethink in t ...

read more Researchers from University College London have found compelling evidence for the first time to link food intolerances and serious illness.A six-month programme has shown potential links with foodstuffs and Crohn's Disease, and ulcerative colitis.The discovery could prompt an entire rethink in t read more Sun Oct 2007 Sun Oct 2007

Kids With Crohn's Disease Find Comfort, Leading-edge Treatment At Pediatric Infusion Center

Categorie : Crohn's
Seventeen-year-old Eliot Drieband explains what it's like to have Crohn's disease a type of inflammatory bowel disease in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for te ...

read more Seventeen-year-old Eliot Drieband explains what it's like to have Crohn's disease a type of inflammatory bowel disease in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for te read more Sun Oct 2007 Sun Oct 2007

Ocera Therapeutics, Inc. Completes Enrollment In FHAST1, A Pivotal Phase 3 Clinical Trial In Fistulizing Crohn's Disease

Categorie : Crohn's
Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn's di ...

read more Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn's di read more Sun Oct 2007 Sun Oct 2007

Patients With Inflammatory Bowel Disease More Likely To Die From Clostridium Difficile Infection

Categorie : Crohn's
A patient with inflammatory bowel disease is four times as likely to die from Clostridium difficile infection compared to a person who does not have the disease, according to an article published ahead of print in the journal Gut (BMJ).The number of new cases of C difficile infection has been steadi ...

read more A patient with inflammatory bowel disease is four times as likely to die from Clostridium difficile infection compared to a person who does not have the disease, according to an article published ahead of print in the journal Gut (BMJ).The number of new cases of C difficile infection has been steadi read more Sun Oct 2007 Sun Oct 2007

Pharmaceutical Benefits Scheme Change For Crohn's Disease

Categorie : Crohn's
A change to the Pharmaceutical Benefits Scheme (PBS) from 1 October 2007 will provide subsidised access to adults and children of Remicade® (infliximab) for the treatment of Crohn's disease.Crohn's disease is an inflammatory disorder of the gastrointestinal tract. It can have a profound impact ...

read more A change to the Pharmaceutical Benefits Scheme (PBS) from 1 October 2007 will provide subsidised access to adults and children of Remicade® (infliximab) for the treatment of Crohn's disease.Crohn's disease is an inflammatory disorder of the gastrointestinal tract. It can have a profound impact read more Sun Oct 2007 Sun Oct 2007

<<< previous | 1 | 2 | 3 | 4 | 5 next >>>



     


Custom Search